NCB003

NCB003 is an antibody-drug conjugate (ADC) currently in preclinical development by NovoCodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine. The drug is engineered using NovoCodex's proprietary site-specific conjugation platform, which facilitates the precise attachment of a cytotoxic payload to a monoclonal antibody or protein. This site-specific approach is designed to produce more homogeneous drug products with potentially improved safety and efficacy profiles compared to traditional random conjugation methods. As of early 2025, NCB003 has completed toxicology sample pilot production and is being investigated for the treatment of various solid tumors and cancers. Specific details regarding its biological target and payload composition remain undisclosed.